

ANALYSIS OF NON-BLEEDING UTERINE FIBROIDS SYMPTOM (NBUFSQ) QUESTIONNAIRE
DURING TREATMENT AND POST-TREATMENT FOLLOW-UP PERIODS
(MODIFIED INTENT-TO-TREAT ANALYSIS SET - COHORT 2)

VARIABLE	TIME POINT	TREATMENT	N	BASE MEAN	VISIT MEAN	WITHIN GROUP			MODEL-BASED BETWEEN GROUP COMPARISON				
						----- CHANGE FROM BASELINE -----			----- COMPARE TO PLACEBO -----				
						MEAN	SD	95% CI	LS MEANS (SE)	DIFFERENCE OF LS MEANS (SE)	95% CI	P-VALUE	\$
SUM OF SCORES OF Q1 TO Q6													
BASELINE													
		PLACEBO	64		13.2				13.2 (1.64)				
		ELAGOLIX 600 MG QD	73		17.7				17.7 (1.54)	4.5 (2.25)	(0.05, 8.90)	0.047*	
		ELAGOLIX 600 MG QD +E2/NETA (LD)	65		14.5				14.5 (1.63)	1.3 (2.31)	(-3.24, 5.86)	0.572	
		ELAGOLIX 600 MG QD +E2/NETA (SD)	72		13.2				13.2 (1.55)	0.1 (2.25)	(-4.37, 4.50)	0.977	

FINAL MONTH #

PLACEBO	66	13.2	12.5	-0.8	11.34	(-3.75, 2.11)	-1.3 (1.19)			
ELAGOLIX 600 MG QD	70	17.7	13.3	-4.0	9.40	(-6.33, -1.74)	-3.3 (1.13)	-2.0 (1.65)	(-5.26, 1.23)	0.223
ELAGOLIX 600 MG QD										
+E2/NETA (LD)	65	14.4	12.0	-3.3	8.09	(-5.42, -1.27)	-3.3 (1.18)	-2.1 (1.68)	(-5.38, 1.22)	0.215
ELAGOLIX 600 MG QD										
+E2/NETA (SD)	61	13.4	10.6	-2.3	10.56	(-4.98, 0.47)	-2.7 (1.19)	-1.4 (1.68)	(-4.75, 1.87)	0.392